2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
about
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer.Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective reviewEfficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-AnalysisSafety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic reviewSEOM clinical guidelines for the treatment of metastatic prostate cancerDocetaxel-based therapy with and without antiangiogenic agents as first-line chemotherapy for castration-resistant prostate cancer: A meta-analysis of nine randomized controlled trials.Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancerMicroRNAs and drug resistance in prostate cancers.Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance.Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review.Chemotherapy in Prostate Cancer.Drug therapies for metastatic castration-resistant prostate cancer.Role of taxanes in advanced prostate cancer.Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.Dose considerations for anti-cancer drugs in metastatic prostate cancer.Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer.Docetaxel in very elderly men with metastatic castration-resistant prostate cancer.A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer.2-weekly docetaxel: issues for clinical practice.Particle replication in nonwetting templates nanoparticles with tumor selective alkyl silyl ether docetaxel prodrug reduces toxicity.Docetaxel in castration-resistant prostate cancer: a single-centre experience.Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.27-Hydroxycholesterol stimulates cell proliferation and resistance to docetaxel-induced apoptosis in prostate epithelial cells.Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.[Chemotherapy of prostate cancer].Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer.Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines.Safety and Efficacy of First-Line Treatments for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Indirect Comparison.Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P2860
Q26852544-148563E2-52BA-47A3-BFC2-D39B8673483BQ27853196-283CAF5B-B2C7-4468-AE11-A02B32DEEFA7Q28545175-591AEFDF-045F-4EC5-92F3-5DE3D56E58D5Q28550301-6C1FBB7F-F500-480E-8D5A-E7E99180215CQ33440646-0206934C-C0B2-4ACE-97C0-0B3A6EAAD974Q34367585-9EE0787B-CE1A-4560-BBEC-DECEF3097ED3Q34553405-F3FE2474-2B3C-4113-B35A-A06FE7EB6DA6Q35298058-B4B435FD-E6A4-4C27-870B-86DE243CA51DQ37232854-C7700098-717F-48A3-BF9B-18BA96CA03F8Q38205266-54FD67FB-18C8-4342-965F-B3648D055DFDQ38232184-20E33C2A-9386-4DFC-B938-AD5D4301769BQ38246587-6218C626-BE53-4C39-8B80-DE85C24FC126Q38374417-4061FB73-55DC-41B1-ACD5-CE14753968C6Q38537545-25B7A40D-4AE5-402A-9ECA-E4C954CE7B1CQ38555581-4BC5A567-76F1-4312-A17E-D383ABEA149EQ38555599-BFC9465A-CF87-4478-8560-1B0B5F4465C1Q38566800-FEA151B0-D65C-403C-B461-5CC2910F6B04Q38726366-86937B87-74A6-4C31-8367-FB36FBA15444Q39347702-38C955E6-54AD-42FB-BEE7-E1A9516CD126Q39397948-D3B253C8-EC8D-4487-B47A-0AF9CA4EA154Q40060365-56813567-CE19-437D-B3FD-88A8B7556718Q41275386-859BAFB2-59F8-4B34-B6AD-35D1A32C9AEAQ41494752-31C7F40D-AFE5-41B3-9781-D9BD0AFBAB44Q42057380-4B91A93B-E73A-4BA2-BD11-2E3AB4004510Q42109453-50007F67-DBC2-4842-8699-A2EF9BEB7270Q44701341-27B550CD-A5AE-47C6-8C33-37BE499BFF15Q47557622-56047512-8C28-46D6-BD46-BDED4ED82004Q48067038-CEEF4C3E-CDB6-4ED0-B53B-82A95541F324Q48272997-6AAFBCB2-12C3-4B29-B564-B2FFBBC7343DQ48310246-4B2B9705-5211-4C30-8308-C80B567C9F9BQ53702293-86815FC8-063E-4B9E-B732-D989EDA12AB9Q53817178-0D50B0CF-F7D5-4C9C-975B-F0729A59D709Q54542174-817C21AE-72B2-4A7A-BDD0-D1CC035256C5Q55379433-95B51A07-3A83-429B-8B84-CAE1B24ED20DQ55380001-F148205A-5881-46D5-969D-D34ED5779613Q57278890-E2FC0A73-6969-4380-90D5-060833281853
P2860
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
2-Weekly versus 3-weekly docet ...... : a randomised, phase 3 trial.
@en
2-Weekly versus 3-weekly docet ...... : a randomised, phase 3 trial.
@nl
type
label
2-Weekly versus 3-weekly docet ...... : a randomised, phase 3 trial.
@en
2-Weekly versus 3-weekly docet ...... : a randomised, phase 3 trial.
@nl
prefLabel
2-Weekly versus 3-weekly docet ...... : a randomised, phase 3 trial.
@en
2-Weekly versus 3-weekly docet ...... : a randomised, phase 3 trial.
@nl
P2093
P50
P1433
P1476
2-Weekly versus 3-weekly docet ...... : a randomised, phase 3 trial.
@en
P2093
Claes Ginman
Fredrik Laestadius
Ilari Lehtinen
John McCaffrey
Katinka Sandberg
Maccon Keane
Marjaana Luukkaa
PROSTY study group
Paul Nyandoto
Petteri Hervonen
P304
P356
10.1016/S1470-2045(12)70537-5
P577
2013-01-04T00:00:00Z